ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.

Cancer Lett

Children's Cancer Research Group, Leeds Institute of Cancer and Pathology, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. Electronic address:

Published: July 2019

Patients with osteosarcoma (OST) frequently relapse with drug resistant disease, consistent with the hypothesis that tumours contain a cancer stem-like cell (CSCs) population that survives chemotherapy to re-populate the tumour at local or metastatic sites. We describe a dual functional approach to isolate OST-CSCs and identify the ABC transporter proteins driving this population to reveal potential targets for the development of new treatments. OST-CSCs were isolated by selection in doxorubicin (OST-EC50 cells) and based on the ability to produce progeny from a single cell (HOS-EC50.SR cells). Pgp expression was increased in OST-EC50 cells, inducing resistance to doxorubicin, etoposide, vincristine and actinomycin D (p < 0.05). Increased expression of ABCG1 and Pgp protein in the HOS-EC50.SR cells induced resistance to etoposide and doxorubicin (p < 0.01), which was directly correlated with ABCG1 expression (r > 0.88, p < 0.001). Pgp expression is increased in both the HOS-EC50 cells where it mediates MDR and the HOS-EC50.SR populations, whereas ABCG1 was only upregulated in the self-renewing drug resistant HOS-EC50.SR cells. Targeting ABCG1 and Pgp may eradicate the drug resistant self-renewing OST-CSCs, leading to improved outcomes for patients with OST.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.011DOI Listing

Publication Analysis

Top Keywords

drug resistant
8
abcg1 pgp
4
pgp identify
4
identify drug
4
resistant self-renewing
4
self-renewing osteosarcoma
4
osteosarcoma cells
4
cells patients
4
patients osteosarcoma
4
osteosarcoma ost
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!